Mab immunotherapies for myeloid leukemia patients with germline or somatic RUNX1 mutations. [ 2018 - ]

Research Grant

Researchers: Prof Hamish Scott (Principal investigator) ,  A/Pr Ian Lewis ,  Dr Anna Brown ,  Dr Hayley Ramshaw ,  Dr Jason Powell
View all 7 related researchers

Brief description This proposal presents preliminary evidence and proposes to confirm that 2 cell surface molecules, CD11a (ITGAL) and IL3RA (CD123) are direct (probably repression) targets of RUNX1 in HSCs, and are dysregulated in RUNX1 mutated AML. Monoclonal antibody therapies that target these two surface molecules have already passed different clinical trial phases for different diseases. We plan to show these antibodies are effective in RUNX1 positive AML in preclinical models and then clinical trials.

Funding Amount $766,995.00

Funding Scheme Project Grants

Notes Standard Project Grant